Vaccine Studies in HIV-infected Subjects

HIV 感染者的疫苗研究

• 批准号: 8148436
• 负责人: Barney Graham
• 金额: $ 55.53万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8148436
• 关键词: DNA; Educational Materials; Eligibility Determination; Enrollment; Goals; HIV-1; Immune response; Individual; Infection; Medication Management; Phase; Recruitment Activity; Screening Result; Therapeutic; Therapeutic Studies; Vaccines

VRC 100 was designed to recruit and screen HIV-infected subjects for therapeutic HIV vaccines, as well as other vaccines to be developed for use in HIV-infected individuals. The results of this screening study were used to determine if the subject met eligibility requirements for participation a vaccine study. Educational materials on vaccines were reviewed with and provided to subjects before enrollment into a vaccine study. VRC 101 was the first Phase I therapeutic study of two candidate HIV-1 vaccines developed by VRC and administered in a prime-boost regimen.

VRC 100 旨在招募和筛选 HIV 感染者，以获取治疗性 HIV 疫苗以及将开发用于 HIV 感染者的其他疫苗。该筛选研究的结果用于确定受试者是否符合参与疫苗研究的资格要求。在参加疫苗研究之前，对疫苗教育材料进行了审查并向受试者提供。 VRC 101 是 VRC 开发的两种候选 HIV-1 疫苗的第一个 I 期治疗研究，并以初免-加强方案进行施用。